Page last updated: 2024-11-05

thalidomide and Vitiligo

thalidomide has been researched along with Vitiligo in 8 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.

Research Excerpts

ExcerptRelevanceReference
"Scientific rationale and encouraging first clinical results suggest the interest of using apremilast for treating vitiligo."9.34Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study. ( Fontas, E; Khemis, A; Lacour, JP; Montaudié, H; Moulin, S; Passeron, T, 2020)
"Scientific rationale and encouraging first clinical results suggest the interest of using apremilast for treating vitiligo."5.34Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study. ( Fontas, E; Khemis, A; Lacour, JP; Montaudié, H; Moulin, S; Passeron, T, 2020)
"Leprosy and vitiligo are common affections in the West Indies."1.31High prevalence of vitiligo in lepromatous leprosy. ( Boisseau-Garsaud, AM; Garsaud, P; Helenon, R; Quist, D; Saint-Cyr, I; Vezon, G, 2000)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's3 (37.50)24.3611
2020's3 (37.50)2.80

Authors

AuthorsStudies
Plachouri, KM1
Kyriakou, G1
Chourdakis, V1
Georgiou, S1
Grafanaki, K1
Khemis, A1
Fontas, E1
Moulin, S1
Montaudié, H1
Lacour, JP1
Passeron, T2
Ezzedine, K1
Vance, TM1
Hamzavi, IH1
Qureshi, AA1
Kim, HJ1
Singer, GK1
Del Duca, E1
Abittan, BJ1
Chima, MA1
Kimmel, G1
Bares, J1
Gagliotti, M1
Genece, J1
Chu, J1
Wilding, G1
Pavel, AB1
Guttman-Yassky, E1
Lebwohl, MG1
Majid, I1
Imran, S1
Batool, S1
Boisseau-Garsaud, AM1
Vezon, G1
Helenon, R1
Garsaud, P1
Saint-Cyr, I1
Quist, D1
Frank, PJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO RAPID VITILIGO[NCT03036995]Phase 280 participants (Actual)Interventional2017-03-20Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for thalidomide and Vitiligo

ArticleYear
One stone, two birds: Improvement of early-onset vitiligo under apremilast in a patient with plaque psoriasis.
    Dermatologic therapy, 2019, Volume: 32, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Early Diagnosis; Humans; Male; Middle Aged; Prognosis; Psor

2019
[What's new in dermatological research?].
    Annales de dermatologie et de venereologie, 2010, Volume: 137 Suppl 4

    Topics: Biomedical Research; Dermatitis, Atopic; Dermatology; Herpesviridae Infections; HIV Infections; Huma

2010

Trials

2 trials available for thalidomide and Vitiligo

ArticleYear
Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.
    The Journal of investigative dermatology, 2020, Volume: 140, Issue:8

    Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Dou

2020
Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study.
    Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:6

    Topics: Humans; Pilot Projects; Skin Pigmentation; Thalidomide; Treatment Outcome; Ultraviolet Therapy; Viti

2021

Other Studies

4 other studies available for thalidomide and Vitiligo

ArticleYear
Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology.
    The Journal of investigative dermatology, 2020, Volume: 140, Issue:8

    Topics: Humans; Prospective Studies; Thalidomide; Treatment Outcome; Ultraviolet Therapy; Vitiligo

2020
Apremilast is effective in controlling the progression of adult vitiligo: A case series.
    Dermatologic therapy, 2019, Volume: 32, Issue:4

    Topics: Adult; Female; Humans; Male; Phosphodiesterase 4 Inhibitors; Thalidomide; Vitiligo

2019
High prevalence of vitiligo in lepromatous leprosy.
    International journal of dermatology, 2000, Volume: 39, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Clofazimine; Dapsone; Female; Humans; Leprostatic Agents; Leprosy, L

2000
Scleroderma.
    Dermatology online journal, 2001, Volume: 7, Issue:1

    Topics: Alopecia Areata; Azathioprine; Biopsy; Bursitis; Colchicine; Diagnosis, Differential; Drug Therapy,

2001